Efficacy of Memantine ER on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-to-severe Alzheimer's Disease

被引：0
|
作者：
Alva, Gustavo [1 ]
Grossberg, George [2 ]
Hendrix, Suzanne [3 ]
Ellison, Noel [3 ]
Andersen, Kristen A. [4 ]
Edwards, John [5 ]
机构：
[1] ATP Clin Res, Costa Mesa, CA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] Pentara Corp, Salt Lake City, UT USA
[4] Prescott Med Commun Grp, Chicago, IL USA
[5] Allergan Plc, Jersey City, NJ USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.087
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease
    Wimo, A
    Winblad, B
    Stoffler, A
    Wirth, Y
    Möbius, HJ
    PHARMACOECONOMICS, 2003, 21 (05) : 327 - 340
  • [42] Meta-analysis of clinical trial data with memantine in moderate to severe Alzheimer's disease
    Winblad, B.
    Jones, R. W.
    Wirth, Y.
    Stoeffler, A.
    Moebius, H. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 71 - 71
  • [43] A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: A responder analysis
    Bullock, R
    Mahableshwarkar, AR
    Lilienfeld, S
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 250 - 251
  • [44] Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease
    Gauthier, Serge
    Lopez, Oscar L.
    Waldemar, Gunhild
    Jones, Roy W.
    Cummings, Jeffrey
    Zhang, Richard
    Schindler, Rachel
    Schwam, Elias
    INTERNATIONAL PSYCHOGERIATRICS, 2010, 22 (06) : 973 - 983
  • [45] Efficacy of Memantine in Moderate to Severe Alzheimer's Disease: Time-to-Event Analysis in a Pooled Population
    Tocco, Michael
    Hendrix, Suzanne
    Miller, Michael L.
    Pejovic, Vojislav
    Graham, Stephen M.
    NEUROLOGY, 2011, 76 (09) : A621 - A621
  • [46] Memantine treatment in a trial of patients with moderate to severe Alzheimer's disease: response across multiple domains
    Schmitt, F.
    Resnick, M.
    Miller, M. L.
    Tocco, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S531 - S531
  • [47] ANALYSIS OF THE EFFECT OF MEMANTINE IN REDUCING CLINICAL SYMPTOMS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE
    Moruzzi, E.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [48] Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
    Farokhnia, Mehdi
    Sabet, Mehdi Shafiee
    Iranpour, Negar
    Gougol, Amirhossein
    Yekehtaz, Habibeh
    Alimardani, Roozbeh
    Farsad, Farzaneh
    Kamalipour, Maryam
    Akhondzadeh, Shahin
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (04) : 351 - 359
  • [49] Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses
    Howard, Robert
    McShane, Rupert
    Lindesay, James
    Ritchie, Craig
    Baldwin, Ashley
    Barber, Robert
    Burns, Alistair
    Dening, Tom
    Findlay, David
    Holmes, Clive
    Jones, Robert
    Jones, Roy
    McKeith, Ian
    Macharouthu, Ajay
    O'Brien, John
    Sheehan, Bart
    Juszczak, Edmund
    Katona, Cornelius
    Hills, Robert
    Knapp, Martin
    Ballard, Clive
    Brown, Richard G.
    Banerjee, Sube
    Adams, Jessica
    Johnson, Tony
    Bentham, Peter
    Phillips, Patrick P. J.
    LANCET NEUROLOGY, 2015, 14 (12): : 1171 - 1181
  • [50] Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
    Waldemar, G.
    Hyvarinen, M.
    Wetterberg, P.
    Korner, A.
    Lehto, H.
    Josiassen, M. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 188 - 188
12345